- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Anavex Life Sciences Corp (AVXL)
Anavex Life Sciences Corp stock price live, this page displays NASDAQ AVXL stock exchange data. View the AVXL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Anavex Life Sciences Corp real time stock price chart below.
What Is the Anavex Life Sciences Corp Stock Price Today?
The Anavex Life Sciences Corp stock price today is 4.515.
What Is the Stock Symbol for Anavex Life Sciences Corp?
The stock symbol for Anavex Life Sciences Corp is "AVXL."
What Stock Exchange Does Anavex Life Sciences Corp Trade On?
Anavex Life Sciences Corp is listed and trades on the NASDAQ stock exchange.
Is Anavex Life Sciences Corp a Good Stock to Buy?
Determining whether Anavex Life Sciences Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVXL quote. (ISIN: US0327973006)
What Is the Anavex Life Sciences Corp Stock Price Today?
The Anavex Life Sciences Corp stock price today is 4.515.
What Is the Stock Symbol for Anavex Life Sciences Corp?
The stock symbol for Anavex Life Sciences Corp is "AVXL."
What Stock Exchange Does Anavex Life Sciences Corp Trade On?
Anavex Life Sciences Corp is listed and trades on the NASDAQ stock exchange.
Is Anavex Life Sciences Corp a Good Stock to Buy?
Determining whether Anavex Life Sciences Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AVXL quote. (ISIN: US0327973006)
4.515
-0.185(-3.94%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.490
4.695
52 wk Range
2.860
13.990
Earnings results expected in 3 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.4904.695
52 wk Range
2.86013.990
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AVXL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
22.000
Upside
+387.26%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Anavex appoints Wolfgang Liedtke as SVP of neurology
- Investing.com
- Anavex appoints Wolfgang Liedtke as SVP of neurology
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Anavex Life Sciences Corp Company Profile
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company’s ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Anavex Life Sciences Corp Earnings Call Summary for Q4/2025
- Anavex reported Q4 2025 net loss of $9.8 million ($0.11/share), with stock rising 5.52% to $3.25 premarket following positive Alzheimer's drug developments
- Blarcamesine demonstrated 30-50% slowdown in cognitive decline for Alzheimer's patients, with the company actively engaged in FDA discussions
- Financial position remains strong with over $120 million cash (3+ year runway), R&D expenses decreased to $7.3 million from $11.6 million YoY
- CEO Dr. Christopher Missling highlighted that 70% of patients experienced 'reversal of negative trajectory of quality of life' with Blarcamesine
- Company plans to present further developments at January conference, focusing on regulatory approvals and market expansion for its oral treatments
Last Updated: 11/25/2025, 10:32 PM
Read Full TranscriptCompare AVXL to Peers and Sector
Metrics to compare | AVXL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVXLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.8x | −1.3x | −0.6x | |
PEG Ratio | 1.63 | 0.03 | 0.00 | |
Price/Book | 4.3x | 1.9x | 2.6x | |
Price / LTM Sales | - | 140.8x | 3.4x | |
Upside (Analyst Target) | 368.1% | 398.1% | 44.9% | |
Fair Value Upside | Unlock | 9.1% | 6.3% | Unlock |
Analyst Ratings
2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 22.000
(+387.26% Upside)
Earnings
Latest Release
Nov 25, 2025
EPS / Forecast
-0.11 / -0.1426
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Anavex Life Sciences (AVXL) Stock Price Today?
The Anavex Life Sciences stock price today is 4.515
What Stock Exchange Does Anavex Life Sciences Trade On?
Anavex Life Sciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Anavex Life Sciences?
The stock symbol for Anavex Life Sciences is "AVXL."
What Is the Anavex Life Sciences Market Cap?
As of today, Anavex Life Sciences market cap is 403.94M.
What Is Anavex Life Sciences's Earnings Per Share (TTM)?
The Anavex Life Sciences EPS (TTM) is -0.54.
When Is the Next Anavex Life Sciences Earnings Date?
Anavex Life Sciences will release its next earnings report on Feb 04, 2026.
From a Technical Analysis Perspective, Is AVXL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Anavex Life Sciences Stock Split?
Anavex Life Sciences has split 2 times.
How Many Employees Does Anavex Life Sciences Have?
Anavex Life Sciences has 34 employees.
What is the current trading status of Anavex Life Sciences (AVXL)?
As of Feb 02, 2026, Anavex Life Sciences (AVXL) is trading at a price of 4.515, with a previous close of 4.700. The stock has fluctuated within a day range of 4.490 to 4.695, while its 52-week range spans from 2.860 to 13.990.
What Is Anavex Life Sciences (AVXL) Price Target According to Analysts?
The average 12-month price target for Anavex Life Sciences is USD22.000, with a high estimate of USD24 and a low estimate of USD20. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +387.26% Upside potential.
What Is the AVXL Premarket Price?
AVXL's last pre-market stock price is 4.690. The pre-market share volume is 5,040.000, and the stock has decreased by -0.010, or -0.210%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.